威尔药业(603351) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥262,865,410.62, a decrease of 5.92% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2022 was ¥17,789,152.14, down 34.94% year-over-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥16,270,113.68, a decline of 38.46% compared to the previous year[3]. - The basic earnings per share for Q3 2022 was ¥0.13, reflecting a decrease of 38.10% year-over-year[4]. - The net profit for Q3 2022 was CNY 77,248,178.32, a decrease of 7.4% compared to CNY 83,384,566.77 in Q3 2021[18]. - The operating profit for Q3 2022 was CNY 88,142,528.77, down 21.9% from CNY 112,796,265.16 in Q3 2021[18]. - The total comprehensive income for Q3 2022 was CNY 77,248,178.32, down from CNY 83,384,566.77 in Q3 2021[19]. - Basic and diluted earnings per share for Q3 2022 were CNY 0.59, a decrease from CNY 0.64 in Q3 2021[19]. Revenue and Costs - Total revenue for the first three quarters of 2022 reached ¥850,975,692.57, an increase of 11.4% compared to ¥764,195,246.66 in the same period of 2021[17]. - Total operating costs for the first three quarters of 2022 were ¥764,101,966.80, up from ¥652,384,213.26 in 2021, reflecting a year-on-year increase of 17.1%[17]. Assets and Liabilities - The total assets as of September 30, 2022, amounted to ¥2,081,052,946.01, representing a 13.01% increase from the end of the previous year[4]. - The total assets of the company reached ¥2,081,052,946.01, up from ¥1,841,426,562.78 at the end of 2021, reflecting a growth of 13.0%[15]. - The company reported a significant increase in total liabilities to ¥618,779,501.63 as of September 30, 2022, compared to ¥456,012,175.77 at the end of 2021, representing a rise of 35.6%[14]. - The company’s total liabilities increased, with a significant rise in borrowings to CNY 360,870,000.00 in Q3 2022 from CNY 170,559,040.00 in Q3 2021[23]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥40,452,488.32[3]. - The cash flow from operating activities for the first three quarters of 2022 was CNY 40,452,488.32, a significant improvement from a negative cash flow of CNY -78,272,989.21 in the same period of 2021[22]. - The company reported a net cash outflow from investing activities of CNY -175,558,816.01 for the first three quarters of 2022, compared to CNY -20,337,564.19 in the same period of 2021[22]. - The cash and cash equivalents at the end of Q3 2022 were CNY 65,576,292.39, down from CNY 90,783,659.51 at the end of Q3 2021[23]. - The company's cash and cash equivalents as of September 30, 2022, were ¥65,576,292.39, slightly down from ¥66,263,015.19 at the end of 2021[12]. Shareholder Information - The top ten shareholders collectively hold 70.77% of the company's shares, with the largest shareholder holding 13.67%[9]. Expenses - The company reported a significant increase in management expenses, contributing to the decline in net profit[6]. - Research and development expenses for the first three quarters of 2022 were ¥36,992,312.72, slightly up from ¥34,926,014.04 in 2021, indicating a focus on innovation[17]. Government Support - The company received government subsidies amounting to ¥2,207,000.00 during the reporting period[6]. Accounts Receivable and Inventory - Accounts receivable increased to ¥148,418,923.32 as of September 30, 2022, compared to ¥120,214,744.95 at the end of 2021, representing a growth of 23.4%[12]. - Inventory levels rose to ¥170,594,791.16, up from ¥142,442,042.74 in 2021, indicating a year-on-year increase of 19.8%[13]. Borrowings - Short-term borrowings surged to ¥328,383,358.80 as of September 30, 2022, compared to ¥171,193,229.29 at the end of 2021, marking an increase of 91.9%[14].